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INTRODUCTION
Psoriasis  is  a  common,  genetically  determined,  inflammatory  and proliferative 
disease  of  the  skin,  the  most  characteristic  lesions  consisting  of  chronic,  sharply 
demarcated, dull red, scaly plaques, particularly on the extensor prominences and in the 
scalp.
The earliest description of what appears to represent psoriasis are given at the 
beginning of medicine in the Corpus Hippocraticum.  Hippocrates used the terms psora 
and lepra for the conditions that can be recognized as psoriasis.  Willan separated two 
diseases as psoriasis entities, a discoid lepra graecorum and a polycyclic confluent psora 
leprosa, which later was called psoriasis.  Von Hebra definitely distinguished the clinical 
picture of psoriasis from that of Hansen’s disease.  
Psoriasis  continues  to  be  a  therapeutic  challenge  in  spite  of  our  growing 
knowledge of its pathogenesis.  Various forms of treatment have been developed in the 
past  several  decades  and  new  regimens  are  constantly  being  tried.   Narrowband 
ultraviolet-B  phototherapy  has  become  an  increasingly  popular  modality   in  the 
treatment  of  psoriasis.  Many  studies  have  documented  improved  efficacy  and 
therapeutic index for narrow band UVB in comparison with conventional broad band 
UVB irradiation.  However the long term side effects of narrowband UVB therapy have 
not  been  fully  documented.   As  a  result,  there  has  been  a  great  deal  of  interest  in 
photocombination therapies that are capable of both reducing the cumulative UVB doses 
and accelerating resolution of skin lesions.  Phototherapy can be combined with topical 
or systemic agents.  Topical agents include anthralin, vitamin D analogues, retinoids, 
glucocorticoids, emollients, salt water baths and tar.                                                      
This study was designed to study the efficacy and safety of narrowband UVB and 
to study the advantages and disadvantages of photocombination with a topical steroid 
and topical tazarotene. `         
REVIEW OF LITERATURE
NARROWBAND UVB PHOTOTHERAPY
HISTORY1 
The ancient egyptians were the first to recognize the beneficial effect of sunlight. 
Newton  in  1672  discovered  the  spectrum  of  visible  light.  Ultraviolet  light  was 
discovered in the early 1700s.  In 1895, modern phototherapy began when Niels Finsen, 
the father of modern phototherapy, used  a carbon arc source to treat lupus vulgaris.  He 
was awarded the Nobel prize in 1903.  In 1923, Dr.Wiliam Goeckerman treated psoriasis 
with  UVB and  crude  coal  tar.   In  1953,   Ingram introduced  his  regime combining 
artificial broadband UVB and dithranol.    In 1978, Wiskemann introduced irradiation 
cabin with broad band UVB tubes for the treatment of psoriasis and uremic pruritus2. 
However the potential  carcinogenic effect  of  broad band UVB made it  less  popular. 
Parish and Jaenicke3 defined the action spectrum for psoriasis with a peak at 313nm. 
The  breakthrough  came  after  1988,  when  narrow  band  UVB  phototherapy  was 
introduced for the treatment of psoriasis by Van Weelden et al and Green et al4.  Since 
then,it has proven to be more effective in various skin disorders and is increasingly used 
in various parts of the world.
ELECTROMAGNETIC SPECTRUM5,6      
Sunlight  comprise  a  spectrum of  electromagnetic  waves   from the  very  short 
cosmic rays, X-rays and gamma rays through ultraviolet light, visible light and infrared 
radiation  to  the  long  radio  and  television  waves.  Ultra  violet  radiation  is  a  small 
component  of  the  electromagnetic  spectrum having  a  wavelength  between  100  and 
400nm. It is further subdivided into
1. UVC: 100 to 280nm
2. UVB: 280 to 315nm 3. UVA: 315 
to 400nm  SOURCE OF NB-UVB7
The source of NB-UVB is Philips TL-01 flourescent bulbs that deliver UVB in the 
range of 310 to 315nm with a peak at 312nm.  It has a relatively narrow spectrum of 
emission and results in a reduction in erythmogenic wavelengths in the 290 to 305nm 
range and 5 to 6 fold increased emission of longer wavelengths, thereby resulting in a 
higher phototherapy index for psoriasis.
EFFECTS OF ULTRAVIOLET RADIATION ON SKIN8
Interaction of light with the skin results in photobiological reactions.  
Photobiological reactions takes place in several steps.
Step 1: Absorption of light by chromophore  
For  a  photobiologic  reaction  to  occur  light  has  to  be  absorbed  by  molecules 
known as chromophores which could be proteins or DNA.  Each chromophore absorbs 
light of specific wavelength, called the absorption spectrum of the chromophore  and the 
wavelength which has the greatest  probability  of  absorption is  called the absorption 
maxima of the chromophore.
Step 2: Excitation to singlet/triplet state        
On  absorption  of  light,  the  chromophore  gets  excited  into  singlet  and  triplet 
excited states.
Step3: Formation of photoproduct
Though the triplet state is short lived it  may initiate a chemical change in the 
chromophore, transforming it into photoproduct.
Step4: Initiation of biochemical reactions
The photoproducts  so formed may initiate  complex biochemical  reactions like 
enzymatic repair , induction of gene products and DNA replication.
Step 5: Cellular response
These  biochemical  reactions  culminate  in  a  cellular  response  like  apoptosis, 
mitosis and differentiation.
Step 6: Clinical response
The final  step  is  the  clinical  manifestations  of  photobiological  reaction  in  the 
form of erythema, hyperplasia, tumour formation etc. 
SKIN PHOTOTYPES9 
Susceptibility  to  sunburn in  sunlight  and  tanning ability  depends on the skin 
phototype of the patient.
Skin phototype          Sunburn susceptibility       Tanning ability
I High None
II High Poor
III Moderate Good
IV Low Very good
V Very low Excellent
VI Very low Excellent
MECHANISM OF ACTION OF NB-UVB
1. Antiproliferative effects10:     
Through  induction  of  DNA  photoproducts  UVR  transiently  inhibits  cell 
proliferation.    
2. Immunomodulatory effects11:
Because  of  shorter  wavelength  ,UVB  rays  have  a  more  superficial  depth  of 
penetration  within  the  skin.  As  a  result,  UVB  primarily  affects  keratinocytes  and 
langerhan cells.  UVB isomerizes epidermal chromophore trans urocanic acid into cis 
urocanic  acid  which  is  responsible  for  the  immunomodulatory  effects12. 
Photoimmunologic effects of UVB fall into three categories:
a. Effects on soluble mediators:
Induces release of soluble immunosuppressive mediators from keratinocytes like 
IL-10 which decreases antigen presenting ability of langerhans cells13,14,15.
b. Modulation of the expression of cell surface associated molecules:  
Modulates  expression  of  adhesion  molecules  like    ICAM-1  which  leads  to 
impaired adherence of langerhans cells and T cells.
c. The induction of apoptosis in pathogenetically relevant cells:
 Induces apoptosis of T cells and langerhans cells.
Depletes langerhans cells and alters antigen presenting capacity.
Decreases peripheral natural killer cell activity and lymphocyte proliferation in 
psoriasis7.  
DOSING SCHEDULE
NB-UVB therapy schedule can be tailored according to the patient’s  skin type 
and local experience.
There are two regimens that are commonly used to determine the initial dose7. 
1.  Involves  determination  of  patient’s  minimal  erythema  dose(MED): 
MED is determined16 by standard method using either the same irradiation device 
or different devices with identical emission spectra.
A template with 20 apertures (10 on each side) of 1.5 x1.5 cm2  is made over the 
back of a cotton suit  used by the operation theatre staff.   The cotton flaps over the 
apertures enable to either shut or keep the apertures open by using Velcro.
All apertures are kept open and back irradiated with 50mJ of NB-UVB. First one 
aperture is closed and thereafter remaining aperture are closed one after the other after 
delivering 50mJ more than the previous aperture.  The dosing schedule of NB-UVB (in 
mJ) is 50, 100, 150, 200, 250, 300, 350, 400, 450, 500.
The readings are taken 24 hours after exposure.  MED is that titrated dose that 
shows  well demarcated erythemic response .                              
The initial dose for NB-UVB should be 70% of MED. Patients are treated 3-5 
times a week.   Although more sittings will  be beneficial,  2-3 sittings are more cost 
effective and hence more acceptable.If the initial dose is tolerated a 20% incremental 
increase of the previous dose is used at each visit.  
When a  previous treatment  results  in  erythema,  no treatment  is  given in  next 
schedule.   Increment  every  second  and  third  sitings  is  also  effective  because  sub-
erythmogenic dose of UVB is also as effective as erythmogenic dose.
2.  Another approach commonly practiced in India involves a standard starting 
dose (280mJ /cm2) with stepwise increase (usually 20%) depending upon the patient’s 
erythema response.   
In case of  mild erythema,  the irradiation dose is held constant  for  subsequent 
treatment or until resolution of symptoms.  The goal of therapy is to achieve persistent 
asymptomatic erythema.
In case of painful erythema with or without edema or blistering further treatment 
is withheld till the symptoms subside.  After resolution of over dose symptoms, the dose 
administered is 50% of the last dose and subsequent increments should be by 10%.
In the photodermatoses, the approach is more cautious with only 10% incremental 
regimen on sun exposure sites.
MAXIMUM DOSE17
In responsive patients NB-UVB can be given for a maximum of 24 months.  After 
one  year,  a  resting  period  of  3  months  is  recommended  to  minimize  the  annual 
cumulative dose of UVB.  In children, the maximum duration allowed is 12 months.
NARROW BAND UVB RESPONSIVE DERMATOSES18
COMMON INDICATIONS
1. Psoriasis
2. Vitiligo
3. Atopic dermatitis
OTHER INDICATIONS
1. Mycosis fungoides
2. Parapsoriasis
3. Generalized lichen planus
4. Pityriasis rosea
5. Pruritus
6. Seborrheic dermatitis
7. Pityriasis rubra pilaris
8. Prurigo nodularis
9. Scleroderma
10. Acquired perforating dermatosis 
FOR PREVENTION OF PHOTODERMATOSES
Prophylactic low dose NB-UVB is beneficial for photosensitive dermatoses like
1. Polymorphic light eruption
2. Actinic prurigo
3. Hydroa vacciniforme 
4. Cutaneous porphyrias
NB-UVB  provides  a  “hardening  photo  protective”  effect.  A  typical  course 
involves 10-25 treatments given in early spring.
Beneficial role has been observed with airborne contact dermatitis to parthenium 
hysterophorus, but it is not always effective19,20.
CONTRA INDICATIONS7
ABSOLUTE:
1. Congenital photosensitivity disorders
2. Lupus erythematosus
3. Pemphigus and Pemphigoid
RELATIVE:
1. Concurrent photosensitivity medications
2. Prior exposure to ionizing radiation
3. History of skin cancer or chronic actinic damage
4. Personal or family history of melanoma
5. Persons with skin type 1
6. Unstable, erythrodermic or pustular psoriasis
ADVERSE EFFECTS OF NB-UVB18
SHORT TERM:
1. Erythema21
2. Pruritus22
3. Blistering of psoriatic plaques23,24
4. Blepharitis and photokeratitis25
5. Recurrent Herpes labialis26
6. Photoallergic dermatitis
7. Worsening of disease 
LONG TERM:
1. Photoaging 
2. Photocarcinogenesis27
3. Immunosuppression
ADVANTAGES OF NB-UVB OVER PUVA7
1. No oral or topical sensitizing drug needed
2. No drug induced side effects and no drug costs
3. No need for post treatment eye protection
4. Safe in pregnancy and children
ADVANTAGES OF NB-UVB OVER BB-UVB
1. Emits  longer  UVB  wavelengths  resulting  in  a  higher  photherapy  index  for 
psoriasis and is more effective than BB-UVB28,29.
2. Less likely to burn3.
3. NB-UVB is capable of more efficiently depleting skin-infiltrating T  cells from 
the epidermis and dermis of psoriatic plaques as compared with BB-UVB12.
NB-UVB IN PSORIASIS
NB-UVB lamps  emit  a  narrow UV band  at  311/312nm thereby  matching the 
closely  assumed  therapeutic  optimum  for  psoriasis4.   NB-UVB  phototherapy  has  a 
higher  therapeutic  to  erythmogenic  ratio  resulting  in  increased  efficacy,  reduced 
incidence of burning and longer remission.  It is a relatively safe method in the treatment 
of psoriasis responding poorly to topical  treatment,  rapidly spreading psoriasis,  wide 
spread psoriasis and severe psoriasis of palms and soles.
COMBINATION THERAPY7
Phototherapy may be combined with topical or systemic agents to achieve higher 
clearance rates, longer disease free intervals and a lower carcinogenic risk30.
TOPICAL AGENTS:   include  anthralin,  tar,  vitamin  D  analogues,  retinoids, 
glucocorticoids, emollients and salt water baths.
Anthralin and tar are not used frequently. 
• The combination of NB-UVB with calcipotriol  increases the therapeutic efficacy of 
phototherapy.   UVB  reduces  the  irritation  caused  by  calcipotriol.  Vitamin  D 
analogues should be applied after phototherapy, because UV light causes degradation 
of vitamin D3.  
• Topical  application  of  emollients   applied  immediately  before  exposure  to  UV 
radiation alters the optical properties of psoriatic lesions improving UV transmission 
and increasing efficacy but care should be taken that they do not act as sunscreens.
• Balneotherapy is the combination of salt water baths with UVB phototherapy.  Salt 
water  baths  are  hampered  by  logistics  (the  requirement  for  bath  tubs)  and 
environmental concerns related to disposal of large amounts of salt.
SYSTEMIC  AGENTS  :  include  retinoids,  glucocorticoids,  cyclosporine  and 
methotrexate.
• Advantages of combining retinoids and uvb are
1. Retinoids exert antipsoriatic effects and act synergistically 
2. They have anticarcinogenic effects and lowers risk due to UVB
• Systemic steroids in combination with UVB is limited to special indications such as 
generalized pustular psoriasis.
• Combination  regimens  of  UVB with  methotrexate  or  cyclosporine  are  used  with 
caution as they may increase the possibility of UV induced skin tumours.
TOPICAL CORTICOSTEROIDS
Topical corticosteroids are the most frequently used drugs in dermatology, since 
the introduction of hydrocortisone by Sulzberger and Witten in 1952. 
STRUCTURE AND CONFIGURATION31
Hydrocortisone  (cortisol)  is  the  parent  compound of  all  derivatives.   It  has  a 
cyclopentenoperhydrophenanthrene nucleus.  Modification of both the ring structure and 
the side chains produced dramatic changes in the potency of the steroid.  Addition of a 
hydroxyl  or  methyl  group  at  the  16th position  will  increase  the  efficacy  without  a 
concomitant increase in the mineralocorticoid effect.  Halogenation at the 9th position, 
allows improved activity within the target cell and decreased breakdown into inactive 
metabolites.
CLASSIFICATION32
The  ability  of  a  given  corticosteroid  agent  to  cause  vasoconstriction  usually 
correlates with its anti-inflammatory potency and thus, vasoconstriction assays are used 
to separate the topical corticosteroids into seven classes based on potency.
CLASS 1- SUPERPOTENT
Betamethasone dipropionate 0.05% optimized vehicle
Clobetasol propionate 0.05%
Diflorasone diacetate 0.05%
Fluocinonide 0.1% optimized vehicle
Flurandrenolide, 4mg/cm2
Halobetasol Propionate 0.05%
CLASS 2 - POTENT
Amcinonide 0.1%
Betamethasone dipropionate 0.05%
Desoximetasone 0.25%
Desoximetasone 0.5%
Diflorasone diacetate 0.05%
Flucinonide 0.05%
Halcinonide 0.1%
Mometasone furoate 0.1%
CLASS 3 – POTENT, UPPER MID STRENGTH
Amcinonide 0.1%
Betamethasone dipropionate 0.05%
Betamethasone valerate 0.1%
Diflorasone diacetate 0.05%
Flucinonide 0.05%
Fluticasone propionate 0.005%
CLASS 4 – MIDSTRENGTH
Betamethasone valerate 0.12%
Clocortolone pivalate 0.1%
Desoximetasone 0.05%
Flucinolone acetonide 0.025%
Flurandrenolide 0.05%
Hydrocortisone probutate 0.1%
Hydrocortisone valerate 0.2%
Mometasone furoate 0.1%
Prednicarbate 0.1%
Triamcinolone acetonide 0.1%
CLASS 5 – LOWER MID STRENGTH
Betamethasone dipropionate 0.05%
Betamethasone valerate 0.1%
Flucinolone acetonide 0.025%
Flurandrenolide 0.05%
Fluticasone propionate 0.05%
Hydrocortisone butyrate 0.1%
Hydrocortisone valerate 0.2%
Prednicarbate 0.1%
Triamcinolone acetonide 0.1%
CLASS 6 – MID STRENGTH
Alclometasone dipropionate 0.05%
Desonide 0.05%
Flucinolone acetonide 0.01%
CLASS 7 – LEAST POTENT
Topicals with dexamethasone, flumethasone, hydrocortisone, methylprednisolone, 
prednisolone 
MECHANISM OF ACTION32
Topical steroids exert their effects through both direct and indirect mechanisms 
which are mediated via the glucocorticoid receptors33 as follows:
1. Steroid diffuses into the target cells and binds to the glucorticoid receptor in the 
cytoplasm.
2. Steroid-receptor complex undergoes necessary conformational changes.
3. The resulting active complex traverses the nuclear envelope and binds to specific 
DNA sequences, the glucocorticoid responsive elements(GRE).  
4. Transcription of specific mRNA and regulation of protein synthesis.
The  metabolic  effects  of  steroids  are  generally  mediated  by  transcriptional 
activity, while the anti-inflammatory effects are mediated by transrepression.
ANTI-INFLAMMATORY ACTION
Steroids exert anti-inflammatory effects by:
• Inhibiting  the  enzyme phospholipase  A2  by  the  induction  of  phospholipase  A2 
inhibitory proteins, collectively called lipocortins
• Inhibiting  transcription  factors(e.g.activator  protein  1  and  nuclear  factor  kB) 
which are involved in the activation of pro-inflammatory genes
• Decreasing the release of IL-1alpha
• Inhibiting phagocytosis
• Stabilizing lysosomal membranes
IMMUNOSUPPRESSIVE EFFECTS
• Steroids suppress the production and effects of humoral factors
• Inhibit leukocyte migration 
• Interfere  with  function  of  endothelial  cells,  granulocytes,  mast  cells,  and 
fibroblasts
• Causes mast cell depletion and decrease the number of Ia langerhan cell
• Reduce T cell proliferation and induce T cell apoptosis 
ANTIPROLIFERATIVE EFFECT
This effect is mediated by inhibition of DNA synthesis and mitosis.
VASOCONSTRICTIVE ACTION
This  is  mediated  by  inhibition  of  natural  vasodilators  such  as  histamine  and 
bradykinin.  Topical steroids cause capillaries in the superficial dermis to constrict thus 
reducing erythema.
ADVERSE EFFECTS32,34
The same mechanism of action responsible for the effectiveness of topical steroids 
are responsible for their adverse effects35.  These include
LOCAL SIDE EFFECTS:
• Epidermal atrophy – fragile skin ,  striae,   telangiectasia,   stellate pseudoscars, 
hypopigmentation
• Impaired wound healing 
• Steroid rebound
• Contact dermatitis36
• Tachyphylaxis
• Glaucoma/cataract
• Facial hypertrichosis
• Folliculitis and miliaria
• Exacerbation  and  increased  susceptibility  to  bacterial,  viral  and  fungal 
infections37: 
1. crusted scabies
2. tinea incognito
3. infantile gluteal granuloma
• Perioral dermatitis, rosacea38 and acneiform eruption
SYSTEMIC SIDE EFFECTS31:
• Suppression of hypothalamic-pituitary-adrenal axis
• Iatrogenic Cushing’s syndrome
• Growth retardation in children
 TACHYPHYLAXIS 37
Tachyphylaxis describes the diminishing effect of a pharmacological agent when 
it is repeatedly used to achieve a clinical response. The vasoconstriction response that is 
seen when first applied to human skin diminishes with subsequent application. Similarly 
depression of DNA synthesis by topical steroids will also show tachyphylaxis. Topical 
steroids suppression of histamine whealing has been described in humans. This can be 
overcome by administering the drug on an intermittent basis.
CONTRAINDICATIONS TO TOPICAL STEROIDS 33
Absolute 
1. Known hypersensitivity to the topical corticosteroids.
2. Known hypersensitivity to a component of the vehicle.
Relative
1. Bacterial, mycobacterial, fungal, viral infection
2. Infestation 
3. Ulceration  
4. Pregnancy and lactation (Should be used with caution at sites other than the breast 
or nipple during lactation)
SAFETY PROFILE
PAEDIATRIC USES39
Topical glucocorticoids are highly effective and fewer side effects are observed 
when a low potency preparation is used for brief periods of time without occlusion in 
children. Infants however are at an increased risk for side effects, likely suppression of 
endogenous  cortisol  production  leading  to  addisonian  crisis  and  growth  retardation 
because of thin skin and inability to metabolise potent steroids rapidly.
GERIATRIC USES40
Elderly patients can have thin skin, which allows for an increased penetration of 
topical steroids. Also, they are more likely to have preexisting skin atrophy due to aging 
and hence precautions are to be taken while giving steroids to elderly. Proper selection 
based  on  several  factors  like  anatomical  site,  potency,  dosage  form,  application 
technique, coexisting infection and atrophy must be done
USES IN PREGNANCY32
Studies on animals shows that when  used in excessive amounts, under occlusion 
for long periods, they are systematically absorbed and can  cause fetal abnormalities. It 
is categorized as ‘C’ drug by F.D.A. It is unknown whether topical steroids are excreted 
in breast milk. They should not be used on the breast prior to breast- feeding.
GUIDELINES FOR USE41
1. Frequency of application
In most instances, applying twice daily of the more potent steroids will suffice. 
The  use  of  daily  or  alternate  day  therapy  should  be  considered,  particularly  with 
extremely potent steroids.
2. Determining the necessary amount
The necessary amount is determined by fingertip unit(FTU) and rule of nine42,43 . 
A fingertip unit is the amount of ointment expressed from a tube with a 5mm diameter 
nozzle, applied from the distal skin crease to the tip of the palmar aspect of the index 
finger.  One FTU weighs 0.49 g  in adult males, and 0.43 g in adult females and covers 
an area of about 300cm2  .  The rule of hand states that an area covered by four adult 
hands(including digits) can be treated by 1 g of ointment or two FTUs.
3. Potency
Plaque type psoriasis  is  a  relatively steroid resistant  dermatoses and often the 
dermatologist must start with a potent agent. Conversely, psoriasis  of the body folds 
with relatively minimal induration and scaling may be steroid sensitive and respond to a 
much less potent agent. One can start with mid potent steroid and later the potency can 
always be increased if the psoriatic plaque fails to respond.
The vasoconstrictor assay is the most commonly employed test to estimate the 
potency of the topical corticosteroid used.
Combination therapies30
Corticosteroids can be combined with the following  to increase the efficacy while 
reducing the incidence of local side effects.
a. Dithranol44
b. Calcipotriene45
c. Tazarotene46
d. Salicylic acid47
e. PUVA
f. UVB
g. Oral retinoids
h. Cyclosporine
TOPICAL TAZAROTENE
INTRODUCTION
Retinoid  is  defined  as  any  molecule  that  by  itself  or  through  metabolic 
conversion,  binds  to  and  activates  the  retinoic  acid  receptors,  thereby  eliciting 
transcriptional  activation  of  retinoic  acid  responsive  genes  that  results  in  specific 
biological responses48.
The history of  the development of  retinoids in dermatology comprise  of three 
generations.  The first is non aromatic retinoids, which include tretinoin (retinoic acid) 
and  isotretinoin  (13  cis  retinoic  acid).   Both  can  be  used  as  topical  or  systemic 
treatment49.
The  second generation  retinoids  are  monoaromatic  retinoids,  etretinate  and its 
metabolite acitretin, which are only effective as systemic treatment.  The  third 
generation  retinoids  are  polyaromatics,  which  include.  adapalene,   tazarotene  and 
bexarotene. 
When topical tretinoin was introduced for acne in 1970s, dermatologists also used 
it to treat psoriasis.  Irritation from retinoids was unacceptable and the use of topical 
retinoids in this setting was never popularized.  It was reported that topical tretinoin 
helped prevent topical corticosteroid atrophy50. Subsequently topical retinoids were used 
to  prevent  topical  corticosteroid  atrophy  in  patients  who  are  dependent  on  topical 
steroids for their psoriasis treatment.  The development of tazarotene led to a renewed 
evaluation of topical  retinoid therapy for psoriasis.   Tazarotene was developed as an 
antipsoriatic  drug  due  to  the  therapeutic  results  of  decreased  scaling  and  plaque 
thickness51,52.
RETINOID RECEPTORS
Retinoids affect gene expression by entering the nucleus and binding with two 
basic type of nuclear receptors belonging to the nuclear receptor superfamily: retinoic 
acid  receptors  (RARs)  and  retinoid  X  recptors  (RXRs)53.   Each  has  three  specific 
subgroups:  α,  β  and γ .  
These receptors bind to regulatory regions in DNA known as Retinoid response 
elements  or  target  sequences  and  activate  gene  transcription  in  a  ligand  dependent 
manner.  Therefore they are referred to as ligand dependent transcription factors48.  The 
retinoid receptors are mainly active as heterodimers of RXR and RAR.  The end result 
of these processes acting on numerous different genes is that retinoids demonstrate a 
tendency to normalize keratinocyte differentiation in diverse circumstances where it is 
disturbed.   
The receptors most abundantly expressed in the epidermis are RAR-γ   and RXR-
α  while RAR-α and RXR-β  are relatively present at low levels54,55.
TAZAROTENE
Tazarotene is a member of the acetylenic retinoids that selectively binds retinoic 
acid recptors(RARs). Tazarotene is the only topical retinoid useful in psoriasis.
PHARMACOKINETICS
Tazarotene  is  a  prodrug  that  is  hydrolyzed  rapidly  in  tissues  to  the  active 
metabolite  termed  tazarotenic  acid.   Topical  tazarotene  produces  high  cutaneous 
concentrations, but the systemic absorption of the prodrug is practically  nonexistent 
because of its rapid metabolism to tazarotenic acid.  Total systemic absorption is up to 
5% of the drug applied in normal  skin and 15% of the amount  applied in  psoriatic 
skin56,57. 
The maximal concentration of tazarotenic acid in the blood occurs 9 hours after 
tazarotene  application.   The  half  life  of  tazarotene  is  less  than  20  minutes.   Small 
amounts of tazarotene, which are absorbed systemically and not degraded, are excreted 
in both the urine and feces.   The degradation of tazarotenic acid is via oxidation to 
inactive sulfoxide and sulfone derivatives that are excreted in the urine.  The terminal 
half life of tazarotenic acid is approximately 18 hours57.
MECHANISM OF ACTION 
Tazarotenic acid has a high affinity to the RAR-γ  nuclear receptor that  is  the 
predominant receptor present in the epidermis.  It also binds to RAR-α and RAR-β  but 
not  to  RXRs.    By  binding  to  the  various  RARs,  tazarotenic  acid  modulates  the 
expression of retinoid responsive genes, including those that regulate cell proliferation, 
cell differentiation, and inflammation58,59.  Tazarotene  downregulates  the  abnormal 
expression  of  keratinocyte  transglutaminase  1  (Tgase  1),  epidermal  growth  factor 
receptor, and hyperproliferative keratins K6 and K1652,60.  
It upregulates the expression of three novel genes, tazarotene inducible gene(TIG-
1, TIG-2, and TIG-3) in patients with psoriasis, which may mediate an antiproliferative 
effect61.
Migration inhibitory factor–related protein (MRP-8), a marker of inflammation, is 
decreased by tazarotene61.
It  blocks the induction of ornithine decarboxylase activity, which is associated 
with cell proliferation and hyperplasia62. It  also  inhibits 
cornified envelope formation and corneocyte accumulation62. 
FORMULATION
Tazarotene is available as both gel and cream, in a concentration of 0.05% and 
0.1%.  The 0.1% tazarotene gel is approved for both acne and psoriasis whereas the 
0.05% tazarotene gel is only approved for psoriasis63.  
EFFICACY OF TAZAROTENE IN PSORIASIS 
Tazarotene is indicated in mild to moderate psoriasis.   It  has a rapid onset  of 
action,  indicated  by  improvement  as  early as  two weeks of  treatment62.   Sustained 
beneficial effects occur for up to 12 weeks after cessation of therapy.  The drug is very 
effective  in  reducing  plaque  thickness  and  clearing  of  psoriatic  lesions.  Psoriatic 
onycholysis  and nail  pitting  also  improves  with  tazarotene64.   Tazarotene  therapy in 
psoriasis is limited by its tendency for cutaneous irritation. It is applied as a thin layer 
over the plaques at bed time and the surrounding normal skin should be protected.
COMBINATIONS30
Tazarotene  can  be  combined  with  topical  steroids  and  phototherapy.  The 
combination  with  a  topical  steroid  enhances  efficacy  and  tolerability.   Use  in 
combination with phototherapy results in greater efficacy than with phototherapy alone.
CONTRAINDICATIONS62
1.  Pregnancy, lactation and women not practicing adequate contraception
2. Hypersensitivity to tazarotene or the vehicle.
3. Eczematous skin, sunburn and exposure to weather extremes.
4.
ADVERSE EFFECTS
Skin irritation, peeling, erythema, dryness, burning and itching are the common 
side effects.   They occur  in up to 30% of patients.  It  is  temporary occurring  most 
commonly during the first 1-2 weeks of theapy and diminishing thereafter.  They can be 
minimized with the use of the cream formulation, alternate day application, short contact 
therapy, mild cleansers and combination therapies and liberal use of emollients65.
Decreased tolerance to UV radiation leading to phototoxic reactions can occur. 
Retinoid dermatitis forming at the periphery of psoriatic plaques and worsening of the 
diseases with photokoebnerisation can cause discomfort to the patient.
Tazarotene  is  safe  from  a  systemic  point  of  view.   No  clinically  significant 
systemic,  ophthalmologic,  hematologic,  or  biochemical  abnormalities  has  been 
reported56.
SAFETY MEASURES  
A pregnancy test is recommended before the use of tazarotene in women of child 
bearing potential and appropriate birth control measures should be in place for the entire 
duration of treatment66.
Concomitant  use  of  irritating  topical  products  such  as  medicated  or  abrasive 
soaps, cosmetics and products with high concentration of alcohol, astringents, spices or 
lime should be avoided.  Also  topical products containing sulfur, resorcinol or salicylic 
acid should be avoided while using topical tazarotene62. 
AIM OF THE STUDY
This  study  was  conducted  in  patients  with  chronic  plaque  type  of   psoriasis 
involving less than 20% of body surface area to evaluate the efficacy and safety of
1. Narrow Band UVB
2.  Narrow Band UVB with topical betamethasone valerate       
3.  Narrow Band UVB with topical tazarotene 
MATERIALS AND METHODS
Sixty patients  who attended the psoriasis out patient clinic at the Department of 
Dermatology, Government General Hospital, Chennai from August 2007 to September 
2009 were included in the study.
The diagnosis of psoriasis was made on clinical grounds and histopathological 
examination.           
SELECTION CRITERIA
Patients with chronic plaque type of psoriasis involving less than 20% of the body 
surface area.
EXCLUSION CRITERIA   
     1. Photosensitive disorders or history of photodamage 
     2. Previous or family history of malignant melanoma
     3. History of exposure to inorganic arsenic or ionizing radiation
     4. Past history of internal or skin malignancy
     5. Pregnant and lactating women
     6. Women contemplating conception
    
All patients were explained about the disease and the benefits and side effects of 
the treatment were discussed with them. 
Consent was obtained from all patients before initiation of treatment. 
All patients were evaluated as follows:
1. History 
2. General examination
3. Systemic examination
4. Dermatological examination
5. Investigations
a. Complete haemogram 
b. Urine analysis
c. Blood sugar, urea, serum creatinine, calcium and uric acid
d. Liver function tests
e. Blood VDRL
f. ELISA for HIV
g. Ophthalmic evaluation
TREATMENT PROTOCOL AND METHODOLOGY:
Sixty patients with chronic plaque type of psoriasis involving less than 20% of 
body surface area were randomly allocated to any one of the following three groups
Group A: Narrow Band UVB phototherapy
Group B: Narrow Band UVB with topical betamethasone valerate 
Group C: Narrow Band UVB with topical tazarotene
GROUP A: NB-UVB GROUP
• 20 Patients were included in this study.
• All patients were asked to wear UV goggles when inside the phototherapy unit.
• Men were advised to protect their genitalia.
• Patients were asked to apply liquid paraffin oil on the plaques of psoriasis prior to 
exposure.
• As all patients were of skin types IV and V,  initial UVB dose of 250 mJ/cm2 was 
started in all patients.
• The manual method for calculation of time (seconds) to set UVB control panel to 
deliver the dose is by the  following equation.
Time (seconds) = Dose (mJ/cm2) / Irradiance (mw/cm2) 
• Patients  were  advised  to  expose  only  the  affected  parts  during treatment  and 
protect other uninvolved areas. 
• Patients were instructed to come out of the chamber when the light switches off 
or if they became uncomfortable during the treatment either due to burning or 
stinging sensation of the skin. 
• If the initial dose was tolerated, subsequent 20% incremental dose was given at 
each subsequent  visit depending on the patient’s erythema response.            
• Treatment was given thrice weekly on non consecutive days.
• Patients were monitored regularly every week.
• Patients were instructed to report immediately if any of the adverse effects were 
noted.
GROUP B: NB-UVB WITH TOPICAL BETAMETHASONE  
• 20 patients were included in this study.
• Patients were advised to apply 0.1% betamethasone valerate ointment once daily 
at bed time.
• Patients were asked to apply the ointment in a thin layer only over the plaques.
• Patients  received  Narrow  Band  UVB  phototherapy  thrice  weekly  similar  to 
patients in group A in addition to topical betamethasone     valerate once daily.
• Patients were monitored regularly every week.
• Patients  were asked to  report  immediately  if  any of  the  adverse  effects  were 
noted.
GROUP C: NB-UVB WITH TOPICAL TAZAROTENE
• 20 patients were included in this study.
• Patients were asked to apply 0.1% tazarotene cream once daily at bed time.
• Patients were asked to apply the cream in a thin layer  only over the plaques.
• Patients  received  Narrow  Band  UVB  phototherapy  thrice  weekly  similar  to 
patients in group A in addition to topical tazarotene once daily at bed time.
• Patients were regularly monitored every week.
• Patients were instructed to report immediately if any of the adverse effects were 
noted.
Efficacy Assessment
Severity and extent of psoriasis were evaluated using “Psoriasis Area and Severity 
Index” (PASI).
Severity of Erythema (E), Desquamation (D) and Induration (I) was recorded on a 
5 point scale as follows:
0 - Nil
1 - Mild
2 - Moderate 
3 - Severe
4 - Very Severe
The area of involvement was recorded on a 7 point scale as follows:
0 - Nil
1 - < 10 %
2 - 10 % - 29 %
3 - 30 % - 49 %
4 - 50 % - 69 %
5 - 70 % - 89 %
6 - 90 % - 100 %
PASI was calculated as follows
PASI = 0.1 ( EH + IH + DH ) AH + 0.2 (EU + IU + DU)AU +
0.3 ( ET + IT + DT ) AT + 0.4 (EL + IL + DL)AL  
A - Area
H - Head
U - Upper Limb
T - Trunk
L - Lower Limb
 
OBSERVATIONS AND RESULTS
Age distribution (Fig.1) 
The mean age in our study was 36.71. The range was from 14 to 76 years. 
Sex distribution (Fig 2, Table 1) 
Males  outnumbered females  in  each of  the  three  groups.  The overall  male  to 
female ratio was observed to be 57% : 43%
Table 1(n=60)
Sex NB-UVB
Betamethasone 
combination
Tazarotene 
combination
Male 11 11 12
Female 9 9 8
Duration of illness (Fig 3)
The mean duration of illness was 42.4 months.  The range was from 3 months to 
120 months.
Family history
Family history was not present in any of the patients in our study.
Nail changes (Fig 4) Totally 27(45%) 
patients had nail involvement, out of which 19(32%) patients had nail pitting
4 patients (7%%) had ridging
3patients (5%) had subungual hyperkeratosis
4 patients(7%) had onycholysis some patients had 
more than one nail changes.
Joint involvement
Four patients in our study had joint involvement, 1 in Narrowband UVB group, 2 
in betamethasone combination group and 1 in tazarotene combination group in the form 
of asymmetrical oligoarthritis.
PASI reduction
The following graphs and tables show the reduction of PASI scores from baseline, 
at  4  weeks,  8weeks,  12weeks  and 16 weeks  in  NB-UVB group and  betamethasone 
combination group (Fig 5, Table2) and        NB-UVB group and tazarotene combination 
group (Fig 6, Table3).
Percentage of PASI reduction
The following graphs and tables show the reduction of PASI  in percentages at 
baseline,  4  weeks  ,  8  weeks,  12  weeks  and  16  weeks  in  NB-UVB  group  and 
betamethasone combination groups (Fig.7, Table 4) and NB-UVB group and tazarotene 
combination groups (Fig.8, Table 5).
From figures 5,7 and tables 2,4 we can see that the baseline PASI scores for  the 
NB-UVB group and betamethasone combination groups are 11.48 and 10.87.  There is 
no statistically significant difference (p>0.05) in baseline PASI among NB-UVB group 
and betamethasone combination group.  There is a decrease in PASI scores at 4, 8, 12 
and 16 weeks to 7.47, 3.96, 2.26, 0.92 and 6.83, 2.9, 1.69 and 0.74 with respect to NB-
UVB group and betamethasone combination group.  This corresponds to a percentage 
reduction to 34.9%, 65.5%, 80.3% and 91.9% in NB-UVB group and 37.1%, 73.3%, 
84.4% and 93.1% in betamethasone combination group.  Here there is no statistically 
significant difference in PASI at 4, 8, 12 and 16 weeks (p>0.05).
PASI REDUCTION
Table 2
Duration
MEAN PASI SCORE
NB-UVB Betamethasone Combination
Baseline 11.48 10.87
4 weeks 7.47 6.83
8 weeks 3.96 2.9
12 weeks 2.26 1.69
16 weeks 0.92 0.74
Fig. 5
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PASI REDUCTION
Table 3
Duration
MEAN PASI SCORE
NB-UVB Tazarotene Combination
Baseline 11.48 11.32
4 weeks 7.47 5.64
8 weeks 3.96 1.70
12 weeks 2.26 0.57
16 weeks 0.92
Fig. 6
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PERCENTAGE REDUCTION IN PASI
Table 4
Duration NB-UVB Betamethasone Combination
Baseline 0 0
4 weeks 34.9 37.1
8 weeks 65.5 73.3
12 weeks 80.3 84.4
16 weeks 91.9 93.1
Fig. 7
Object 3
PERCENTAGE REDUCTION IN PASI
Table 5
Duration NB-UVB
Tazarotene 
Combination
Baseline 0 0
4 weeks 34.9 50.1
8 weeks 65.5 84.9
12 weeks 80.3 94.9
16 weeks 91.9
Fig. 8 
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From figures 6, 8 and tables 3, 5 we can see that the mean baseline PASI scores 
for NB-UVB group and tazarotene combination group are 11.48 and 11.32 respectively. 
There is no statistically  significant  difference (p>0.05) in baseline PASI among NB-
UVB group and tazarotene combination group .  At 4 weeks, PASI scoring has reduced 
to 7.47 and 5.64 respectively for the above mentioned groups.  Thus there is more than 
50% reduction in the tazarotene combination group whereas only 34.9% reduction in 
NB-UVB group.  There is a further fall in PASI scoring at 8 weeks to 3.96 and 1.70 in 
NB-UVB group and tazarotene combination groups which correspond to reduction in 
percentages of 65.5% and 84.9%  respectively.  A further reduction in PASI score is 
observed at 12 and 16 weeks to 2.26 and 0.92 in the NB-UVB group which corresponds 
to a percentage reduction to 80.3% and 91.9%.  In the tazarotene combination group, the 
reduction  in  PASI  is  more  rapid  with  mean  PASI  score  of  0.57  at  12  weeks 
corresponding to a percentage reduction of 94.9%.  There is a statistically significant 
difference (p<0.05) in PASI between NB-UVB  and tazarotene combination group at 4, 
8 and 12 weeks. 
Duration of treatment and mean cumulative dose
The mean cumulative dose, average number of exposures and total duration of 
treatment are tabulated.
Table 6
GroupA
(NB-UVB)
GroupB 
(Betamethasone 
combination)
GroupC
( Tazarotene 
combination)
Average number 
of exposure
34.8 33.7 25.2
Duration of 
treatment(weeks)
11.6 11.5 8.8
Mean cumulative 
dose (J/cm2)
43.3 40.2 25.1
Response to therapy Based 
on the percentage reduction in PASI the results were graded as excellent (100%), good 
(75-100%), moderate (50-75%) and poor(<50%).  The results seen in our study has been 
tabulated (Table7,8 &9).
Group A (NB-UVB) 
Table 7
Result No. of patients Percentage
% reduction in 
PASI score at 
16 weeks
Excellent 10 53 100
Good 6 31 75-100
Moderate 1 5 50-75
Poor response 2 11 <50
In group A-
Out  of  20  patients,  10  patients  had  complete  clearance,  6  patients  had  good 
response and 1 had moderate response.   2 patients  had poor  response and 1 patient 
discontinued therapy due to unknown reasons.
Group B (NB-UVB with topical betamethasone)
Table 8
Result No. of patients Percentage
% reduction in 
PASI score at 
16 weeks
Excellent 12 63 100
Good 4 21 75-100
Moderate 1 5 50-75
Poor response 2 11 <50
In group B- 
Out of 20 patients, 12 patients had complete clearance, 4 had good response, 1 
had moderate response and 2 had poor response. One patient discontinued treatment due 
to unknown reasons.
Group C (NB-UVB with topical tazarotene)
Table 9
Result No. of patients Percentage
% reduction in 
PASI score at 12 
weeks
Excellent 15 88 100
Good 1 6 75-100
Moderate 1 6 50-75
Poor response - - <50
In group C- 
Out  of  20  patients,  15  patients  had  complete  clearance,  1  patient  had  good 
response and 1 patient had moderate response.  Three patients discontinued treatment 
due to unknown reasons.
Adverse effects (Table 10)
Adverse effects noted in our study has been tabulated.
Table 10
Adverse effect Group A Group B Group C
Pruritus 2 1 1
Erythema 1 1 2
Initial 
exacerbation
1 1 1
Irritation 0 0 4
Pruritus and erythema was noted  in all the three groups.  Initial exacerbation was 
noticed in one patient in each group and it gradually resolved with continuation of the 
therapy. 
Irritation was seen in 4 patients in the tazarotene combination group.  It was mild 
and resolved with liberal use of emollients.
DISCUSSION
At the present time, phototherapy with narrow band UVB is considered one of the 
most  effective therapeutic modalities for patients with psoriasis.   Many studies have 
documented improved efficacy and therapeutic index for narrowband UVB.  However, 
the long term side effects of narrowband UVB therapy have not been fully documented. 
As a result, there has been a great deal of interest in photocombination therapies that are 
capable  of  both reducing cumulative UVB doses and accelerating resolution of  skin 
lesions.  To gain our experience, this study was designed to compare NB-UVB therapy 
with a combination of      NB-UVB and topical agents.
TREATMENT RESPONSE
 In group A (NB-UVB), the mean baseline PASI score was 11.48  and the mean 
PASI score at the end of 16weeks was 0.92. There was 91.9% reduction in PASI score at 
the end of 16 weeks.  10 patients showed complete clearance and 6 patients showed 
more than 75% clearance. The side effects were also few and treated symptomatically. 
This shows that NB-UVB is highly effective and safe in psoriasis.  Though our study 
was of low number, the results were consistent with the previous studies21,67.
Group A (NB-UVB) was compared with group B (NB-UVB with betamethasone 
valerate)  and  group  C  (NB-UVB  with  tazarotene).   The  final  evaluation  involved 
comparison of both treatments according to the response, cumulative dose and adverse 
effects.  The response of the patients ranged from excellent (complete clearance) to poor 
response(<50% decrease in PASI score).  In our study, the basic demographic data in all 
the three groups were similar.
When  NB-UVB  group  was  compared  with  NB-UVB  and  betamethasone 
combination group, there was no significant difference (p>0.05) in PASI scores at 4, 8, 
12 and 16 weeks.  The mean duration of treatment  was 11.6 weeks in the NB-UVB 
group and 11.5 weeks in the NB-UVB with betamethasone group.  The mean cumulative 
dose of NB-UVB in our study was  43.3J/cm2 in NB-UVB  group and 40.2J/cm2 in NB-
UVB with betamethasone group.  This explains that there is no significant difference 
between these two groups with respect to PASI reduction, duration of treatment and the 
mean cumulative dose.  .  
According to literature and previous studies10,68,69 done, use of topical steroids with 
UVB does not add much long term benefit.  In our study also, although there was some 
initial reduction in thickness and a rapid initial response, there was no difference in the 
duration of treatment and the mean cumulative dose when compared to NB-UVB alone.
When NB-UVB group was compared with NB-UVB and tazarotene combination 
group, there was a significant difference (p<0.05) in PASI scores at 4weeks, 8 weeks and 
12 weeks. At 4 weeks, there was more than 50% reduction in PASI in the tazarotene 
combination group and only 34.9% reduction in NB-UVB group.  There was further 
reduction to 84.9% and 94.9% at the end of 8 weeks and 12 weeks respectively in the 
tazarotene  combination  group  while  there  was  only  65.5% and  80.3% reduction  at 
8weeks and 12 weeks respectively in the NB-UVB group.  This explains that there was a 
rapid  fall  in  PASI  score  in  tazarotene  combination  group.    The  mean  duration  of 
treatment  was 8.8 weeks in the tazarotene combination group and 11.6 weeks in the 
NB-UVB group.  The mean cumulative dose was 25.1J/cm2 in tazarotene combination 
group and 43.3J/cm2 in the NB-UVB group.  This explains that tazarotene combination 
group showed a faster clearance with a lesser cumulative dose.  
Koo et  al  reported that  tazarotene  plus  NB-UVB phototherapy is  significantly 
more  effective  than NB-UVB phototherapy  alone  for  the  treatment  of  psoriasis  and 
mean cumulative UVB exposure required is significantly lower when tazarotene was 
combined70.  The same observations were reported by Behrens et al71.  In our study also, 
tazarotene combination proved to be more effective than NB-UVB monotherapy and 
achieved faster clearance with lesser cumulative dose.
POOR RESPONSE
Poor response was seen in 2 patients each in the NB-UVB group and NB-UVB 
with betamethasone groups.  It correlates with the long duration of illness and it has no 
correlation with PASI score at the initiation of therapy.
SIDE EFFECTS
The adverse effects in our study were minimal and none of the patients required 
discontinuation of therapy.  In our study, the common side effects noted were pruritus, 
erythema and initial exacerbation .  The adverse effect profile observed in our study was 
similar to that reported in the literature.
Significant erythema was noted in only 4 of our patients, one each in NB-UVB 
group and NB-UVB with betamethasone group and 2 in tazarotene combination group 
but according to literature and other western studies9,21 the common side effect of UV 
therapy is erythema. This significant difference is probably because all our patients are 
of skin type IV and V.
Initial exacerbation was noted in 3 of our patients, one in each group but newer 
lesions  ceased  to  appear  with  continuation  of  therapy.   This  could  be  due  to 
immunomodulatory effect of NB-UVB.
Pruritus was noted in 4 of our patients initially which subsided with regular use of 
emollients and continuation of therapy.  It  is  assumed to be related to prostaglandin 
release.
Irritation was the common side effect noted in the tazarotene  combination group in the previous studies70,71  and 
also in our study but it  was very mild and managed with liberal use of emollients.  Tazarotene combination was well  
tolerated, with only 3 patients discontinuing therapy due to unknown reasons.
CONCLUSION
• Narrow Band UVB phototherapy is an effective modality of treatment in plaque 
type of psoriasis.
• Narrow Band UVB is safe and well tolerated in our patients with very few side 
effects.
• Combining NB-UVB phototherapy and topical  betamethasone valerate  confers 
little advantage in treating psoriasis and appears to have no substantial effect on 
the time to clearing or the mean cumulative dose.
• Combination  of  tazarotene  and  NB-UVB  phototherapy  is  significantly  more 
effective than NB-UVB phototherapy alone for the treatment of psoriasis.
• The  addition  of  tazarotene  to  NB-UVB  therapy  promotes  faster  clearing  of 
psoriasis when compared with NB-UVB monotherapy.
• The cumulative dose of NB-UVB is reduced when tazarotene is combined with it 
which means a lower risk for long term complications.
• Irritation due to tazarotene is mild and  combination of tazarotene with NB-UVB 
is well tolerated.
• Photocombination therapies can broaden the therapeutic options for the treatment 
of patients with psoriasis.
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PROFORMA
Name:  Date:
                                                          
Age/Sex: OP No:
Occupation:  Case No:
Address: 
HISTORY
Duration:
Itching : ð  Yes   No
H/O Previous treatment : ð  Topical ð  Systemic
EXACERBATION WITH:
 ð  Cold climate                       ð  Sunlight                      ð  Dialysis
 ð  Infection                             ð  Trauma                       ð  Emotional factors
 ð  Puberty                               ð  Pregnancy                  ð  Menopause
PAST HISTORY
 ð  Hypertension                     ð  Diabetes                         ð  Tuberculosis
 ð  Photosensitivity                ð  Cutaneous malignancy    ð  Radiotherapy
Drugs taken for any other condition :      ð Yes            ð  No
     Name of the drug:  
     Duration of treatment:
FAMILY HISTORY : ð  Mother  ð  Father
ð  Sibling ð  Others
PERSONAL HISTORY : ð  Alcohol  ð  Smoking
Menstural history:
ð  Pregnancy ð  Lactation
GENERAL EXAMINATION:
        ð  Pallor                    ð  Icterus                       ð  Edema
           Pulse :                       BP:                                Weight: 
SYSTEMIC EXAMINATION:
     CVS:
      RS:
      P/A:
     
     CNS:
     ENT:
     Dental:
DERMATOLOGICAL EXAMINATION:
     Skin lesions:   Site
                             Morphology
                             Surface area involved
                             Auspitz sign:  Yes/No
    
     Mucous membrane:
    
      Palms and soles:
     
     Scalp:
     
     Hair:
     
     Nail:
     
    Joint involvement:
        
Area and severity assessment by PASI scoring:
Erythema/Infiltration/Desquamation Scoring Area Scoring 
0 - Nil 0 – Nil
1 - Mild 1 – 0%-9%
2 - Moderate 2 – 10 % - 29%
3 - Severe 3 – 30 % - 49 %
4 - Very Severe           4 – 50 % - 69 %
5 – 70 % - 89 %
6 – 90 % - 100 %  
PASI      = 0.1 (EH + IH + DH) AH + 0.2 (EU + IU + DU) AU  
0.3 (ET + IT + DT) AT   + 0.4 (EL + IL + DL) AL
INVESTIGATIONS:
 
Ophthalmological examination:
Skin Biopsy:
 
Haemoglobin:
 Total count:
 Differential count:
 ESR:
 Blood sugar:               
 Urea:                  
 Creatinine:
 Serum calcium:          
 Uric acid:
 Blood VDRL:             
 HIV:
 LFT:   
NB-UVB chart:
Date Cycle Dose Duration Cumulative 
dose
Side 
effects
FOLLOW UP:
Weeks PASI Score Cumulative dose
0
4
8
12
16
KEY TO MASTER CHART
F - Female
M      - Male
Mon - Months
Yrs     - Years
P        - Pitting
R        - Ridging
SUH   - Sub ungual hyperkeratosis
O        - Onycholysis
Y        - Yes
AO     - Asymmetrical oligoarthritis
PASI  - Psoriasis Area and Severity Index
SE      - Side effects
PR      -  Prurritus
IE       - Initial exacerbation
E        - Erythema
IR       -  Irritation
ABBREVIATIONS
UVB - Ultra violet B
NB-UVB - Narrow band  ultra violet B
BB-UVB - Broad band ultra violet B
UVA - Ultra violet A
MED - Minimal erythema dose
RAR - Retinoic acid receptor
RXR - Retinoid X receptor
PASI - Psoriasis Area and Severity Index
